Published • loading... • Updated
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
Summary
13 Articles
13 Articles
The shares of Danish pharmaceutical company Novo Nordisk, manufacturer of Ozempic and Wegovy, plummeted by about 6% this Monday on the Copenhagen Stock Exchange, after the company presented to investors its strategy for the coming years. The titles fell by up to 7% during the session. In its capital ... Continue reading "Ozempic manufacturer plummets on the Stock Exchange in the face of competition and the end of patents"
·Madrid, Spain
Read Full Article
Novo Touts Future Blockbuster Launches, Disappointing Investors
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
·New York, United States
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left1Leaning Right2Center5Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
13%
C 62%
R 25%
Factuality
To view factuality data please Upgrade to Premium
